Protection against marked plasma leakage in dengue haemorrhagic fever by infusion of carbazochrome sodium sulfonate (AC-17).
Patients diagnosed clinically as having grade II dengue haemorrhagic fever, and confirmed serologically to have been recently infected by dengue virus were randomly assigned to two groups, to assess suppression of plasma leakage by intravenous administration of carbazochrome sodium sulfonate(AC-17). The double-blind prospective study over three successive epidemic periods included 39 patients in the placebo group, and 38 in the AC-17 group. The effects of the administration were evaluated with respect to pleural effusion of the chest X-ray films. A clear difference between the two groups was found in the numbers of patients with pleural effusion and severity of the pleural effusion thus the administration of AC-17 may be useful in eliminating the risk factors of severe bleeding and shock in dengue haemorrhagic fever.
D000323:Adrenochrome / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002199:Capillary Permeability / Q000187:drug effects*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003715:Dengue / Q000188:drug therapy* / Q000503:physiopathology; D004311:Double-Blind Method; D006801:Humans; D007223:Infant; D010996:Pleural Effusion / Q000209:etiology / Q000517:prevention & control*; D011446:Prospective Studies; D011897:Random Allocation
D000323:Adrenochrome; C073338:carbazochrome